FiercePharma | Nachrichten

Zeit	Aktuelle Nachrichten
Fr	NICE blames BioMarin for Brineura rejection after price talks break down
Fr	Takeda gout drug Uloric loses first-line approval after FDA confirms death risks
Fr	Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
Fr	Catalyst plays the R&D card to defend Firdapse's $375K sticker against Bernie Sanders' ire
Fr	Bayer to cut 200 jobs at U.S. logistics center as it alters course for pharma
Fr	FiercePharmaAsia-GSK-Bharat vaccine deal; Dr. Reddy's rollercoaster; Sandoz sells U.S. generics
Do	Congressman aims to break pharma's insulin 'pricing monopoly' by legalizing Canadian imports
Do	Novo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can't launch until 2020
Do	Justice Department, SEC subpoenas put J&J's talc woes under federal microscope
Do	Bristol-Myers confirms activist Starboard has its shares. And it wants board seats, too
Do	It's not a Brexit problem, Sanofi says of epilepsy drug shortages
Do	Despite 35 price hikes, Sanofi's net prices fell yet again in 2018
Mi	Allogene Therapeutics to build out facility for allogeneic CAR T treatments
Mi	Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study
Mi	'Organic' growth and 'pivoting' at Bausch Health? One analyst begs to disagree
Mi	Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Mi	Teva, FTC enter expanded settlement barring certain 'pay-for-delay' deals for 10 years
Mi	Emergex preps for synthetic vaccines human testing with new R&D facility and key hire
Mi	Merck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk
Mi	News of Note - Facebook, flu vaccines and more
Di	Philippine officials pull Dengvaxia's marketing license, but Sanofi asks them to reconsider
Di	Former AstraZeneca UK plant back up for sale, putting 270 jobs at risk
Di	Under-pressure Allergan backs a CEO-chairman job split-just not right now
Di	Activist Starboard wants to know if Bristol investors support Celgene buy: report
Di	Pipeline-hungry Bayer antes up on Vitrakvi, just as Roche's would-be rival gets faster FDA review

Zeit

Aktuelle Nachrichten

NICE blames BioMarin for Brineura rejection after price talks break down

Takeda gout drug Uloric loses first-line approval after FDA confirms death risks

Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?

Catalyst plays the R&D card to defend Firdapse's $375K sticker against Bernie Sanders' ire

Bayer to cut 200 jobs at U.S. logistics center as it alters course for pharma

FiercePharmaAsia-GSK-Bharat vaccine deal; Dr. Reddy's rollercoaster; Sandoz sells U.S. generics

Congressman aims to break pharma's insulin 'pricing monopoly' by legalizing Canadian imports

Novo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can't launch until 2020

Justice Department, SEC subpoenas put J&J's talc woes under federal microscope

Bristol-Myers confirms activist Starboard has its shares. And it wants board seats, too

It's not a Brexit problem, Sanofi says of epilepsy drug shortages

Despite 35 price hikes, Sanofi's net prices fell yet again in 2018

Allogene Therapeutics to build out facility for allogeneic CAR T treatments

Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study

'Organic' growth and 'pivoting' at Bausch Health? One analyst begs to disagree

Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report

Teva, FTC enter expanded settlement barring certain 'pay-for-delay' deals for 10 years

Emergex preps for synthetic vaccines human testing with new R&D facility and key hire

Merck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk

News of Note - Facebook, flu vaccines and more

Philippine officials pull Dengvaxia's marketing license, but Sanofi asks them to reconsider

Former AstraZeneca UK plant back up for sale, putting 270 jobs at risk

Under-pressure Allergan backs a CEO-chairman job split-just not right now

Activist Starboard wants to know if Bristol investors support Celgene buy: report

Pipeline-hungry Bayer antes up on Vitrakvi, just as Roche's would-be rival gets faster FDA review

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von FiercePharma